Ellomay Capital Reports Results for the Fourth Quarter and Full Year of 2021

<br /> Ellomay Capital Reports Results for the Fourth Quarter and Full Year of 2021<br />

PR Newswire


TEL-AVIV, Israel

,

March 31, 2022

/PRNewswire/ —

Ellomay Capital Ltd.

(NYSE American: ELLO) (TASE: ELLO)

(“Ellomay” or the “Company”)

,


a renewable energy and power generator and developer of renewable energy and power projects in

Europe

and

Israel

,


today reported its unaudited financial results for the fourth quarter and year ended

December 31

,

20

2

1

.


The Talasol Refinancing

In

January 2022

, Talasol Solar S.L. (”

Talasol

“), completed a refinancing (the ”

Refinancing

“) of its project finance by closing of a Facilities Agreement in the aggregate amount of €175 million provided by European institutional lenders (the ”

Talasol New Financing

“) and early repayment in full of the outstanding €121 million under the previous Talasol project finance (the ”

Talasol Previous Financing

“). The weighted average life of the Talasol New Financing is approximately 11.5 years, compared to an original weighted average life of 5.5 years of the Talasol Previous Financing. The Talasol New Financing bears a fixed annual interest rate at a weighted average of approximately 3%, compared to a variable interest rate that was fixed at an average of approximately 3% by an interest rate swap contract in the Talasol Previous Financing.

Although the Talasol New Financing achieved financial closing in

January 2022

, as the Refinancing was highly probable to be completed, our financial results as of and for the year ended

December 31, 2021

were impacted, mainly as follows: (i) the Talasol Previous Financing in the amount of approximately €121 million was presented as current liabilities, (ii) the fair value of the interest rate swap contract associated with the Talasol Previous Financing in the amount of approximately €3.3 million was recorded as a financing expense and presented as a current liability, (iii) the expected payment of dividend to Talasol’s minority shareholders in the amount of approximately €15 million was presented as a current liability, and (iv) the Company amortized the outstanding balance of expenses that were capitalized to the Talasol Previous Financing in the aggregate amount of approximately €12.2 million. In January, the proceeds on account of the Talasol New Financing were used to repay the outstanding balance of €121 million that was presented as a current liability and the Talasol New Financing was recorded as a long term liability.


Financial Highlights

  • Revenues were approximately €44.8 million for the year ended

    December 31

    , 202

    1

    , compared to approximately €9.6 million for the year ended

    December 31

    , 20

    20

    . The revenue increase is mainly attributable to the achievement of PAC (preliminary acceptance certificate) of the photovoltaic plant held by Talasol Solar S.L. (the ”

    Talasol PV Plant

    “) on

    January 27, 2021

    , upon which the Company commenced recognition of revenues. The increase is also attributable to the Groen Gas Gelderland B.V. biogas facility (the ”

    Gelderland Biogas Plant

    “) acquisition, in

    December 2020

    and to improved operational efficiency at the Company’s biogas plants in

    the Netherlands

    .
  • Operating expenses were approximately €17.5 million for the year ended

    December 31

    , 202

    1

    , compared to approximately €5 million for the year ended

    December 31

    , 20

    20

    . This increase is mainly attributable to the achievement of PAC of the Talasol PV Plant on

    January 27, 2021

    , and the Gelderland Biogas Plant acquisition in

    December 2020

    . Depreciation expenses were approximately €15.1 million for the year ended

    December 31, 2021

    , compared to approximately €3 million for the year ended

    December 31, 2020

    .
  • Project development costs were approximately €2.5 million for the year ended

    December 31, 2021

    , compared to approximately €3.5 million for the year ended

    December 31, 2020

    . This decrease is mainly due to capitalization of expenses in connection with the project to construct a 156 MW pumped storage hydro power plant in the Manara Cliff,

    Israel

    (the ”

    Manara PSP

    “).
  • General and administrative expenses were approximately €5.7 million for the year ended

    December 31, 2021

    , compared to approximately €4.5 million for the year ended

    December 31, 2020

    . The increase is mostly due to increased D&O liability insurance costs and an increase in the management fee paid to the Company’s Chairman and CEO, as well as Talasol’s general and administrative expenses following the achievement of PAC of the Talasol PV Plant on

    January 27, 2021

    .
  • Company’s share of profits of equity accounted investee, after elimination of intercompany transactions, was approximately €0.12 million for the year ended

    December 31, 2021

    , compared to approximately €1.5 million for the year ended

    December 31, 2020

    . This decrease is mainly attributable to the decrease in revenues of Dorad Energy Ltd. (”

    Dorad

    “) and higher financing expenses incurred by Dorad as a result of the CPI indexation of loans from banks.
  • Other income was 0 in the year ended

    December 31, 2021

    , compared to other expenses, net, of approximately €2.1 million in the year ended

    December 31, 2020

    . The other income recorded in 2020 was due to a cancellation of a provision for potential indemnification recorded in this amount during 2019 in connection with the sale of our Italian subsidiaries.
  • Financing expenses, net were approximately €26.9 million for the year ended

    December 31, 2021

    , compared to approximately €3.6 million for the year ended

    December 31, 2021

    . The increase in financing expenses, net, was mainly due to the following:

    – Financing expenses in connection with the Talasol PV Plant, previously capitalized to fixed assets, are recognized in profit and loss starting from the PAC, consisting of (i) approximately €2.2 million of interest of bank loans, (ii) approximately €0.9 million of swap related payments, (iii) approximately €0.3 million of expenses in connection with Talasol’s project financing, and (iv) approximately €2.1 million of interest accrued on shareholder loans granted by the minority shareholders of Talasol.

    – An amount of approximately €15.5 million recorded as of

    December 31, 2021

    in connection with the Talasol Refinancing. Such expenses include approximately €3.3 million recorded in connection with the termination of the interest rate swap contract and €12.2 million in connection with the amortization of the outstanding balance of expenses that were capitalized to the Talasol previous project finance.

    – Approximately €0.9 million of expenses in connection with the early repayment of the Company’s Series B Debentures.
  • Tax benefit was approximately €2.5 million in the year ended

    December 31, 2021

    , compared to tax benefit of approximately €0.1 million in the year ended

    December 31, 2020

    . The increase in tax benefit was mainly due to the expenses recorded by the Talasol PV Plant in connection with the expected prepayment of the Talasol previous project finance.
  • Net loss was approximately €20.3 million in the year ended

    December 31, 2021

    , compared to net loss of approximately €6.2 million for the year ended

    December 31, 2020

    .
  • Total other comprehensive loss was approximately €4.5 million for the year ended

    December 31, 2021

    , compared to total other comprehensive income of approximately €2.3 million in the year ended

    December 31, 2020

    . The change was mainly due to changes in fair value of cash flow hedges and from foreign currency translation differences on NIS denominated operations, due to fluctuations in the euro/NIS exchange rates.
  • Total comprehensive loss was approximately €24.8 million in the year ended

    December 31, 2021

    , compared to total comprehensive loss of approximately €3.9 million in the year ended

    December 31, 2020

    .
  • EBITDA was approximately €19.2 million for the year ended

    December 31, 2021

    , compared to approximately €0.3 million for the year ended

    December 31, 2020

    .
  • Net cash from operating activities was approximately €15.2 million for the year ended

    December 31, 2021

    , compared to net cash used in operating activities of approximately €5.8 million for the year ended

    December 31, 2020

    . The increase in net cash from operating activities is mainly attributable to the achievement of PAC of the Talasol PV Plant on

    January 27, 2021

    , upon which the Company commenced recognition of revenues and expenses.
  • On

    October 25, 2021

    , the Company issued additional Series C Debentures in an aggregate principal amount of

    NIS 120,000 thousand

    (approximately €32,100 thousand) to Israeli classified investors in a private placement for an aggregate gross consideration of approximately

    NIS 121,600 thousand

    (approximately €32,529 thousand), reflecting a price of

    NIS 1.0135

    per

    NIS 1

    principal amount.
  • As of

    March 10, 2021

    , the Company held approximately €78.8 million in cash and cash equivalents, approximately €1.9 million in marketable securities, €27.7 million in short term deposits and approximately €15.4 million in restricted short-term and long-term cash.


Fiscal 2021 CEO Review

Ran Fridrich, CEO and a board member of the Company, provided the following CEO review:

“In 2021 the Company met its business plan goals, which included among other things:

  • Operating the Talasol PV Plan for the year, with PAC achieved on

    January 27, 2021

    , with an average availability of 98%;
  • Refinancing the debt of the Talasol PV Plant under improved interest, term and repayment terms, which enabled an immediate repayment of shareholders’ loans to Talasol’s shareholders, including the Company (51%), in the aggregate amount of approximately €30 million and is expected to substantially increase the dividend paid by Talasol to its shareholders on an annual basis;
  • Financial closing and commencement of construction of the Manara PSP, with the tunneling construction works advancing as planned;
  • Constructing the Ellomay Solar PV project in

    Spain

    (28 MW) and reaching the final construction stage (the project’s connection to the national grid is currently underway);
  • Developing a scope of 439 MW licenses for PV projects in

    Italy

    under advanced development, of which approximately 120 MW received licenses as of this date. The construction of the first project (20 MW) commenced during 2022 and works will commence on another adjacent project (15 MW) shortly;
  • Locating properties in

    Israel

    for the construction of the PV + storage projects of 40MW PV + 80MW/h batteries (the first tender is in advanced stages); and
  • Continued operational improvements in our biogas facilities in

    the Netherlands

    , including a 20% improvement in output in the Gelderland Biogas Plant.

The financing expenses for the year included non-recurring expenses in connection with the refinancing of the Talasol project finance (in the aggregate amount of approximately €15.5 million) and changes in exchange rates (approximately €5.4 million), which are not cash items. The financing expenses of the Company excluding these expenses were approximately €8 million.

Main financial metrics, in line with the Company’s projections:

  • Non-IFRS Revenues – approximately €51.2 million.
  • Adjusted EBITDA – approximately €

    25

    .

    5

    million.
  • Adjusted FFO – approximately €

    18

    .

    5

    million.
  • Cash flow from operating activities – approximately €15.2 million.”

Please see the tables on page 12 of this press release for a reconciliation of this information.


Use of NON-IFRS Financial Measures

Non-IFRS Revenues, EBITDA, Adjusted EBITDA and Adjusted FFO are non-IFRS measures. EBITDA is defined as earnings before financial expenses, net, taxes, depreciation and amortization and Adjusted FFO is calculated by deducting tax expenses and interest expenses on bank loans, debentures and others from the Adjusted EBITDA. The Company uses the terms “Non-IFRS Revenues,” “Adjusted EBITDA” and “Adjusted FFO” to highlight the fact that in the calculation of these Non-IFRS financial measures the Company presents the results of the Talmei Yosef PV Plant under the fixed asset model and not under IFRIC 12, presents its share in Dorad based on distributions of profit and not on the basis of equity gain using the equity method and includes the financial results of Talasol for the period prior to achievement of PAC that were not recognized in the profit and loss statement based on accounting rules. The Company presents these measures in order to enhance the understanding of the Company’s operating performance and to enable comparability between periods. While the Company considers these non-IFRS measures to be important measures of comparative operating performance, these non-IFRS measures should not be considered in isolation or as a substitute for net income or other statement of operations or cash flow data prepared in accordance with IFRS as a measure of profitability or liquidity. These non-IFRS measures do not take into account the Company’s commitments, including capital expenditures and restricted cash and, accordingly, are not necessarily indicative of amounts that may be available for discretionary uses. In addition, Adjusted FFO does not represent and is not an alternative to cash flow from operations as defined by IFRS and is not an indication of cash available to fund all cash flow needs, including the ability to make distributions. Not all companies calculate Non-IFRS Revenues, EBITDA, Adjusted EBITDA or Adjusted FFO in the same manner, and the measures as presented may not be comparable to similarly-titled measures presented by other companies. The Company’s Non-IFRS Revenues, EBITDA, Adjusted EBITDA and Adjusted FFO may not be indicative of the Company’s historic operating results; nor is it meant to be predictive of potential future results. The Company uses these measures internally as performance measures and believes that when these measures are combined with IFRS measures they add useful information concerning the Company’s operating performance. A reconciliation between results on an IFRS and non-IFRS basis is provided on page 12 of this press release.


About Ellomay Capital Ltd.

Ellomay is an Israeli based company whose shares are registered with the NYSE American and with the Tel Aviv Stock Exchange under the trading symbol “ELLO”. Since 2009, Ellomay Capital focuses its business in the renewable energy and power sectors in

Europe

and

Israel

.

To date, Ellomay has evaluated numerous opportunities and invested significant funds in the renewable, clean energy and natural resources industries in

Israel

,

Italy

and

Spain

, including:

  • Approximately 7.9MW of photovoltaic power plants in

    Spain

    and a photovoltaic power plant of approximately 9 MW in

    Israel

    ;
  • 9.375% indirect interest in Dorad Energy Ltd., which owns and operates one of

    Israel’s

    largest private power plants with production capacity of approximately 860MW, representing about 6%-8% of

    Israel’s

    total current electricity consumption;
  • 51% of Talasol, which owns a photovoltaic plant with a peak capacity of 300MW in the municipality of Talaván, Cáceres,

    Spain

    ;
  • Groen Gas Goor B.V., Groen Gas Oude-Tonge B.V. and Groen Gas Gelderland B.V., project companies operating anaerobic digestion plants in the

    Netherlands

    , with a green gas production capacity of approximately 3 million, 3.8 million and 9.5 million (with a license to produce 7.5 million) Nm3 per year, respectively;
  • 83.333% of Ellomay Pumped Storage (2014) Ltd., which is constructing a 156 MW pumped storage hydro power plant in the Manara Cliff,

    Israel

    .

For more information about Ellomay, visit

http://www.ellomay.com

.


Information Relating to Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company’s management. All statements, other than statements of historical facts, included in this press release regarding the Company’s plans and objectives, expectations and assumptions of management are forward-looking statements.  The use of certain words, including the words “estimate,” “project,” “intend,” “expect,” “believe” and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company’s forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by the Company’s forward-looking statements, including the impact of the Covid-19 pandemic on the Company’s operations and projects, including in connection with steps taken by authorities in countries in which the Company operates, changes in the market price of electricity and in demand, regulatory changes, changes in the supply and prices of resources required for the operation of the Company’s facilities (such as waste and natural gas) and in the price of oil, and technical and other disruptions in the operations or construction of the power plants owned by the Company. These and other risks and uncertainties associated with the Company’s business are described in greater detail in the filings the Company makes from time to time with Securities and Exchange Commission, including its Annual Report on Form 20-F. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.


Contact:

Kalia Rubenbach (Weintraub)

CFO

Tel: +972 (3) 797-1111

Email:

[email protected]


Ellomay Capital Ltd. and its Subsidiaries



Condensed Consolidated Statements of Financial Position



December 31,



2021



2020



2021



Audited



Audited



Audited



€ in thousands



Convenience Translation into

US$ in thousands*



Assets



Current assets:


Cash and cash equivalents



41,229


66,845



46,663


Marketable securities



1,946


1,761



2,202


Short term deposits



28,410


8,113



32,154


Restricted cash



1,000





1,132


Receivable from concession project



1,784


1,491



2,019


Trade and other receivables



9,487


9,825



10,737



83,856


88,035



94,907



Non-current assets


Investment in equity accounted investee



34,029


32,234



38,514


Advances on account of investments



1,554


2,423



1,759


Receivable from concession project



26,909


25,036



30,456


Fixed assets



340,065


264,095



384,886


Right-of-use asset



23,367


17,209



26,447


Intangible asset



4,762


4,604



5,390


Restricted cash and deposits



15,630


9,931



17,690


Deferred tax



12,952


3,605



14,659


Long term receivables



5,388


2,762



6,098


Derivatives



2,635


10,238



2,982



467,291


372,137



528,881



Total assets



551,147


460,172



623,788



Liabilities and Equity



Current liabilities


Current maturities of long term bank loans



126,180


10,232



142,811


Current maturities of long term loans



16,401


4,021



18,563


Current maturities of debentures



19,806


10,600



22,416


Trade payables



2,904


12,387



3,285


Other payables



20,806


**3,593



23,548


Current maturities of derivatives



14,783


**1,378



16,731


Current maturities of lease liabilities



4,329


**490



4,900



205,209


42,701



232,254



Non-current liabilities


Long-term lease liabilities



15,800


17,299



17,882


Long-term loans



39,093


134,520



44,245


Other long-term bank loans



37,221


49,396



42,127


Debentures



117,493


72,124



132,979


Deferred tax



8,836


7,806



10,001


Other long-term liabilities



3,905


**2,964



4,420


Derivatives



10,107


8,336



11,439



232,455


292,445



263,093



Total liabilities



437,664


335,146



495,347



Equity


Share capital



25,605


25,102



28,980


Share premium



85,883


82,401



97,202


Treasury shares



(1,736)


(1,736)



(1,965)


Transaction reserve with non-controlling Interests



5,697


6,106



6,448


Reserves



7,288


4,164



8,249


Retained earnings (accumulated deficit)



(7,217)


8,191



(8,168)


Total equity attributed to shareholders of the Company



115,520


124,228



130,746


Non-Controlling Interest



(2,037)


798



(2,305)



Total equity



113,483


125,026



128,441



Total liabilities and equity



551,147


460,172



623,788


*

Convenience translation into US$ (exchange rate as at

December 31

, 20

21

:

euro 1

= US$

1.132

)

** Reclassified


Ellomay Capital Ltd. and its Subsidiaries



Condensed Consolidated Statements of Comprehensive Loss



For the three

months ended

December 31,




For the year



ended December 31,




For the three

months ended

December 31,



For the year

ended December 31,



2021



2020



2021



2020



2021



2021



Unaudited



Audited



Unaudited



Audited



€ in thousands (except per share data)



Convenience Translation into US$*


Revenues



12,017


2,801



44,783


9,645



13,601



50,685


Operating expenses



(5,874)


(1,541)



(17,524)


(4,951)



(6,648)



(19,834)


Depreciation and amortization expenses



(4,028)


(731)



(15,076)


(2,975)



(4,559)



(17,063)



Gross profit



2,115


529



12,183


1,719



2,394



13,788


Project development costs



(663)


(479)



(2,508)


(3,491)



(750)



(2,839)


General and administrative expenses



(1,712)


(1,186)



(5,661)


(4,512)



(1,938)



(6,407)


Share of profits of equity accounted investee



(167)


(380)



117


1,525



(189)



132


Other income (expenses), net






2,100






2,100











Operating profit (loss)



(427)


584



4,131


(2,659)



(483)



4,674


Financing income



585


802



2,931


2,134



662



3,317


Financing income (expenses) in connection with derivatives

and warrants, net



(438)


(438)



(841)


1,094



(496)



(952)


Financing expenses in connection with projects finance



(12,276)


(497)



(17,800)


(1,823)



(13,894)



(20,146)


Financing expenses in connection with debentures



(420)


(765)



(3,220)


(2,155)



(475)



(3,644)


Interest expenses on minority shareholder loan



(551)


(5)



(2,055)


(41)



(624)



(2,326)


Other financing expenses



(3,346)


(441)



(5,899)


(2,843)



(3,787)



(6,676)


Financing expenses, net



(16,446)


(1,344)



(26,884)


(3,634)



(18,614)



(30,427)



Loss before taxes on income



(16,873)


(760)



(22,753)


(6,293)



(19,097)



(25,753)


Tax benefit



3,041


285



2,489


125



3,442



2,817



Loss for the period



(13,832)


(475)



(20,264)


(6,168)



(15,655)



(22,936)



Loss attributable to:


Owners of the Company



(8,347)


(216)



(15,408)


(4,627)



(9,447)



(17,439)


Non-controlling interests



(5,485)


(259)



(4,856)


(1,541)



(6,207)



(5,498)



Loss for the period



(13,832)


(475)



(20,264)


(6,168)



(15,654)



(22,937)



Other comprehensive income (loss) items



That after initial recognition in comprehensive

income (loss) were or will be transferred to profit

or loss:


Foreign currency translation differences for foreign operations



6,696


801



12,284


(482)



7,579



13,903


Effective portion of change in fair value of cash flow hedges



(783)


(1,443)



(13,429)


2,210



(886)



(15,199)


Net change in fair value of cash flow hedges transferred to


profit or loss



(1,481)


(163)



(3,353)


555



(1,676)



(3,795)


Total other comprehensive profit (loss)



4,432


(805)



(4,498)


2,283



5,017



(5,091)



Total other comprehensive income (loss)


attributable to:


Owners of the Company



5,260


87



3,124


881



5,954



3,535


Non-controlling interests



(828)


(892)



(7,622)


1,402



(937)



(8,626)



Total other comprehensive income (loss)



4,432


(805)



(4,498)


2,283



5,017



(5,091)



Total comprehensive loss for the year



(9,400)


(1,280)



(24,762)


(3,885)



(10,637)



(28,028)



Total comprehensive


loss for the


year


attributable to:


Owners of the Company



(3,087)


(129)



(12,284)


(3,746)



(3,493)



(13,904)


Non-controlling interests



(6,313)


(1,151)



(12,478)


(139)



(7,144)



(14,124)



Total comprehensive


loss for the year



(9,400)


(1,280)



(24,762)


(3,885)



(10,637)



(28,028)



Basic loss per share



(0.65)


(0.01)



(1.20)


(0.38)



(0.75)



(1.39)



Diluted loss per share



(0.65)


(0.01)



(1.20)


(0.38)



(0.75)



(1.39)


* Convenience translation into US$ (exchange rate as at

December 31, 2021

:

euro 1

=

US$ 1.132

)


Ellomay Capital Ltd. and its Subsidiaries



Condensed Consolidated Statements of Changes in Equity



Attributable to shareholders of the Company



Non- controlling



Total



Interests



Equity



Share

capital



Share

premium





Accumulated

Deficit



Treasury

shares



Translation

reserve from





foreign

operations



Hedging

Reserve



Interests

Transaction

reserve with





non-controlling

Interests



Total






in thousands



For the year ended



December 31, 202



1



(Audited):



Balance as at January 1, 202



1




25,102



82,401



8,191



(1,736)



3,823



341



6,106



124,228



798



125,026



Profit (loss) for the year











(15,408)



















(15,408)



(4,856)



(20,264)



Other comprehensive loss for the year



















11,542



(8,418)







3,124



(7,622)



(4,498)



Total comprehensive loss


for the year











(15,408)







11,542



(8,418)







(12,284)



(12,478)



(24,762)



Transactions with owners of the Company,

recognized directly in equity:



Issuance of ordinary shares



































8,682



8,682



Acquisition of shares in subsidiaries from non-controlling interests



(409)



(409)



961



552



Warrants exercise



454



3,419



3,873







3,873



Options exercise



49



























49







49



Share-based payments







63























63







63



Balance as at December 31, 202



1




25,605



85,883



(7,217)



(1,736)



15,365



(8,077)



5,697



115,520



(2,037)



113,483



For the three months



ended December 31, 202



1



(Unaudited):



Balance as at September 30, 202



1




25,578



85,774



1,130



(1,736)



9,093



(7,065)



5,145



117,919



4,276



122,195



Profit (loss) for the year











(8,347)



















(8,347)



(5,485)



(13,832)



Other comprehensive loss for the year



















6,272



(1,012)







5,260



(828)



4,432



Total comprehensive loss


for the year











(8,347)







6,272



(1,012)







(3,087)



(6,313)



(9,400)



Transactions with owners of the Company, recognized directly in equity:



Acquisition of shares in subsidiaries from non-controlling interests



























552



552







552



Issuance of ordinary shares







71























71







71



Options exercise



27



























27







27



Share-based payments







38























38







38



Balance as at December 31, 202



1




25,605



85,883



(7,217)



(1,736)



15,365



(8,077)



5,697



115,520



(2,037)



113,483


Ellomay Capital Ltd. and its Subsidiaries



Condensed Consolidated Interim Statements of Changes in Equity (cont’d)



Attributable to shareholders of the Company



Non- controlling



Total



Interests



Equity



Share

capital



Share

premium





Retained

earnings



Treasury

shares



Translation

reserve from





foreign

operations



Hedging

Reserve



Interests

Transaction

reserve with





non-controlling

Interests



Total






in thousands



For the year ended



December 31, 20



20





(Audited):



Balance as at



January 1, 20



20





21,998


64,160


12,818


(1,736)


4,356


(1,073)


6,106


106,629


937


107,566



Profit (loss) for the year






(4,627)










(4,627)


(1,541)


(6,168)



Other comprehensive loss for the year










(533)


1,414




881


1,402


2,283



Total comprehensive loss for the year






(4,627)




(533)


1,414




(3,746)


(139)


(3,885)



Transactions with owners of the Company,

recognized directly in equity:



Issuance of ordinary shares


3,084


18,191












21,275




21,275



Options exercise


20














20




20



Share-based payments




50












50




50



Balance as at December 31, 20



20



25,102


82,401


8,191


(1,736)


3,823


341


6,106


124,228


798


125,026



For the three months



ended December 31, 2020 (Unaudited):



Balance as at



September 30, 20



20





25,102


82,379


8,407


(1,736)


2,963


1,114


6,106


124,335


1,949


126,284



Profit (loss) for the period






(216)










(216)


(259)


(475)



Other comprehensive loss for the period










860


(773)




87


(892)


(805)



Total comprehensive income for the period






(216)




860


(773)




(129)


(1,151)


(1,280)



Transactions with owners of the Company, recognized directly in equity:



Issuance of ordinary shares























Options exercise























Share-based payments




22












22




22



Balance as at December 31, 20



20



25,102


82,401


8,191


(1,736)


3,823


341


6,106


124,228


798


125,026


Ellomay Capital Ltd. and its Subsidiaries



Condensed Consolidated Interim Statements of Changes in Equity (cont’d)



Attributable to shareholders of the Company



Non- controlling



Total



Interests



Equity



Share

capital



Share

premium





Accumulated

Deficit



Treasury

shares



Translation

reserve from





foreign

operations



Hedging

Reserve



Interests

Transaction

reserve with





non-controlling

Interests



Total



Convenience translation into US$ (exchange rate as at December 31, 2021: euro 1 = US$ 1.132)



For the year ended



December 31, 2021 (Audited):



Balance as at January 1, 2021



28,411



93,261



9,271



(1,965)



4,327



387



6,911



140,603



905



141,508



Profit (loss) for the year











(17,439)



















(17,439)



(5,498)



(22,937)



Other comprehensive loss for the year



















13,063



(9,528)







3,535



(8,626)



(5,091)



Total comprehensive loss


for the year











(17,439)







13,063



(9,528)







(13,904)



(14,124)



(28,028)



Transactions with owners of the Company,

recognized directly in equity:



Issuance of ordinary shares



































9,826



9,826



Acquisition of shares in subsidiaries from non-controlling interests



























(463)



(463)



1,088



625



Warrants exercise



514



3,870























4,384







4,384



Options exercise



55



























55







55



Share-based payments







71























71







71



Balance as at December 31, 2021



28,980



97,202



(8,168)



(1,965)



17,390



(9,141)



6,448



130,746



(2,305)



128,441



For the three months



ended December 31, 2021 (Unaudited):



Balance as at September 30, 2021



28,949



97,079



1,279



(1,965)



10,291



(7,996)



5,823



133,460



4,839



138,299



Profit (loss) for the year











(9,447)



















(9,447)



(6,207)



(15,654)



Other comprehensive loss for the year



















7,099



(1,145)







5,954



(937)



5,017



Total comprehensive loss


for the year











(9,447)







7,099



(1,145)







(3,493)



(7,144)



(10,637)



Transactions with owners of the Company, recognized directly in equity:



Acquisition of shares in subsidiaries from non-controlling interests



























625



625







625



Warrants exercise







80























80







80



Options exercise



31



























31







31



Share-based payments







43























43







43



Balance as at December 31, 2021



28,980



97,202



(8,168)



(1,965)



17,390



(9,141)



6,448



130,746



(2,305)



128,441


Ellomay Capital Ltd. and its Subsidiaries



Condensed Consolidated Interim Statements of Cash Flow



For the three

months ended

December 31,



For the year ended

December 31,



For the three

months ended

December 31,



For the year ended

December 31,



2021



2020



2021



2020



2021



2021



Unaudited



Audited



Unaudited



Audited






in thousands



Convenience Translation into US$*



Cash flows from operating activities


Profit for the period



(13,832)


(475)



(20,264)


(6,168)



(15,654)



(22,937)



Adjustments for

:


Financing expenses, net



16,446


1,344



26,884


3,634



18,614



30,428


Profit from settlement of derivatives contract









(407)









(461)


Depreciation and amortization



4,028


731



15,076


2,975



4,559



17,063


Share-based payment transactions



38


22



63


50



43



71


Share of profits of equity accounted investees



167


380



(117)


(1,525)



189



(132)


Payment of interest on loan from an equity accounted investee









859


582







972


Change in trade receivables and other receivables



4,542


(3,137)



(1,883)


(3,868)



5,141



(2,131)


Change in other assets



(345)


(205)



(545)


179



(390)



(617)


Change in receivables from concessions project



267


203



1,580


1,426



302



1,788


Change in trade payables



167


529



154


190



189



174


Change in other payables



(4,834)


(2,063)



2,380


(1,226)



(5,471)



2,694


Tax benefit



(3,041)


(285)



(2,489)


(125)



(3,442)



(2,817)


Income taxes paid



(79)


(31)



(94)


(119)



(89)



(106)


Interest received



517


761



1,844


2,075



585



2,087


Interest paid



(1,701)


(1,325)



(7,801)


(3,906)



(1,925)



(8,829)



16,172


(3,076)



35,504


342



18,305



40,184


Net cash from (used in) operating activities



2,340


(3,551)



15,240


(5,826)



2,651



17,247



Cash flows from investing activities


Acquisition of fixed assets



(10,232)


(24,742)



(82,810)


(128,420)



(11,581)



(93,724)


Acquisition of subsidiary, net of cash acquire






(7,464)






(7,464)










VAT associated with the acquisition of fixed assets



(2,310)











(2,614)






Repayment of loan from an equity accounted investee






55



1,400


1,978







1,585


Loan to an equity accounted investee



(39)


(181)



(335)


(181)



(44)



(379)


Advances on account of investments



8








(1,554)



9






Proceeds from marketable securities






436






1,800










Acquisition of marketable securities






(1,481)






(1,481)










Proceeds from settlement of derivatives, net



(724)





(976)





(819)



(1,105)


Proceed (investment) in restricted cash, net



(5,786)


742



(5,990)


23,092



(6,549)



(6,779)


Investment in short term deposit



(27,132)


84



(18,599)


(1,323)



(30,708)



(21,050)


Proceeds (Investment) in Marketable Securities



(1,897)





(112)





(2,147)



(127)


Compensation as per agreement with Erez Electricity Ltd.












1,418











Net cash used in investing activities



(48,112)


(32,551)



(107,422)


(112,135)



(54,453)



(121,579)



Cash flows from financing activities


Issuance of warrants



2,346


2,224



3,746


2,544



2,655



4,240


Repayment of long-term loans and finance lease obligations



(18,927)


(1,193)



(18,905)


(3,959)



(21,422)



(21,397)


Repayment of Debentures



(29,411)





(30,730)


(26,923)



(33,287)



(34,780)


Cost associated with long term loans



(35,311)


(734)



(2,796)


(734)



(39,965)



(3,165)


Proceeds from options



10,799





49


20



12,222



55


Sale of shares in subsidiaries to non-controlling interests



32,130





1,400







36,365



1,585


Issuance of ordinary shares












21,275










Payment of principal of lease liabilities



(8,478)





(4,803)





(9,595)



(5,436)


Proceeds from long term loans, net



37,033


9,520



32,947


111,357



41,914



37,289


Proceeds from issue of convertible debentures









15,571









17,623


Proceeds from issuance of Debentures, net



32,252


38,057



57,717


38,057



36,503



65,324



Net cash from financing activities



22,433


47,874



54,196


141,637



25,390



61,338


Effect of exchange rate fluctuations on cash and cash equivalents



6,515


1,084



12,370


(1,340)



7,374



14,002


Increase (decrease) in cash and cash equivalents



(16,824)


12,856



(25,616)


22,336



(19,041)



(28,992)


Cash and cash equivalents at the beginning of the period



58,053


53,989



66,845


44,509



65,704



75,655



Cash and cash equivalents at the end of the period



41,229


66,845



41,229


66,845



46,663



46,663

* Convenience translation into US$ (exchange rate as at

December 31, 2021

:

euro 1

=

US$ 1.132

)



Ellomay Capital Ltd. and its Subsidiaries



Operating Segments



PV



Total



Ellomay



Bio



reportable



Total



Italy



Spain



Solar[1]



Talasol



Israel[2]



Gas



Dorad



Manara



segments



Reconciliations



consolidated



For the year ended December 31, 2021



€ in thousands



Revenues







2,587







28,494

[3]




4,255



12,686



51,630







99,652



(54,869)



44,783


Operating expenses







(472)







(6,239)



(367)



(10,446)



(39,175)







(56,699)



39,175



(17,524)


Depreciation expenses







(904)







(10,546)



(2,374)



(3,135)



(5,539)







(22,498)



7,422



(15,076)



Gross profit (loss)







1,211







11,709



1,514



(895)



6,916







20,455



(8,272)



12,183


Project development costs



(2,508)


General and


administrative expenses



(5,661)


Share of loss of equity


accounted investee



117



Operating profit



4,131


Financing income



2,931


Financing expenses in connection


with derivatives and warrants, net



(841)


Financing expenses, net



(28,974)



Loss before taxes



on Income



(22,753)



Segment assets as at



December 31, 2021



1,715



13,841



14,456



246,172



38,809



34,570



118,435



107,678



575,676



(24,529)



551,147


Ellomay Capital Ltd. and its Subsidiaries



Reconciliation of Loss to EBITDA (unaudited)



For the three months

ended December 31,



For the year

ended December 31,



For the three months

ended December 31,



For the year

ended December 31,



2021



2020



2021



2020



2021



2021






in thousands



Convenience Translation into US$*



Net loss for the period



(13,832)


(475)



(20,264)


(6,168)



(15,654)



(22,937)



Financing expenses, net



16,446


1,344



26,884


3,634



18,614



30,428



Tax benefit



(3,041)


(285)



(2,489)


(125)



(3,442)



(2,817)



Depreciation and amortization



4,028


731



15,076


2,975



4,559



17,063



EBITDA



3,601


1,315



19,207


316



4,077



21,737

* Convenience translation into US$ (exchange rate as at

December 31, 2021

:

euro 1

=

US$ 1.132

)



Reconciliation of Loss to Adjusted EBITDA and to Adjusted FFO (unaudited)



For the year ended December 31, 2021






in thousands


Loss for the period



(20,264)


Financing expenses, net



26,884


Tax benefit



(2,489)


Depreciation



15,076


Adjustment to the Share of loss of equity accounted investee to include the Company’s share in distributions



2,142


Adjustment to the revenues of the Talmei Yosef PV Plant due to calculation based on the fixed asset model



3,239


Adjustment to include the financial revenues of the Talasol for the period prior to achievement of PAC that were not recognized in the profit and loss statement based on accounting rules



895


Adjusted EBITDA



25,483


Interest and SWAP expenses on bank loans and debentures



(6,959)


Adjusted FFO



18,524




Reconciliation of IFRS Revenues to Non-IFRS Revenues (unaudited)



For the year ended December 31, 2021






in thousands


IFRS Revenues for the period



44,783


Adjustment to the Share of loss of equity accounted investee to include the Company’s share in distributions



2,259


Adjustment to the revenues of the Talmei Yosef PV Plant due to calculation based on the fixed asset model



3,239


Adjustment to include the financial revenues of the Talasol for the period prior to achievement of PAC that were not recognized in the profit and loss statement based on accounting rules



895


Non-IFRS Revenues



51,176

Ellomay Capital Ltd. and its Subsidiaries



Information for the Company’s Debenture Holders

Pursuant to the Deeds of Trust governing the Company’s Series C and Series D Debentures (together, the ”

Debentures

“), the Company is required to maintain certain financial covenants. For more information, see Items 5.B and 10.C of the Company’s Annual Report on Form 20-F submitted to the Securities and Exchange Commission on March 31, 2021 and below.


Net Financial Debt

As of

December 31, 2021

, the Company’s Net Financial Debt, (as such term is defined in the Deeds of Trust of the Company’s Debentures), was approximately €68.1 million (consisting of approximately €223.3[4] million of short-term and long-term debt from banks and other interest bearing financial obligations, approximately €139.7[5] million in connection with the Series C Debentures issuances (in July 2019,

October 2020

,

February 2021

and

October 2021

) and Series D Debentures issuance (in

February 2021

), net of approximately €71.6 million of cash and cash equivalents, short-term deposits and marketable securities and net of approximately €223.3[6] million of project finance and related hedging transactions of the Company’s subsidiaries).


Information for the Company’s Series C Debenture Holders.

The Deed of Trust governing the Company’s Series C Debentures includes an undertaking by the Company to maintain certain financial covenants, whereby a breach of such financial covenants for two consecutive quarters is a cause for immediate repayment. As of

September 30, 2021

, the Company was in compliance with the financial covenants set forth in the Series C Deed of Trust as follows: (i) the Company’s shareholders’ equity was approximately €113.5 million, (ii) the ratio of the Company’s Net Financial Debt (as set forth above) to the Company’s CAP, Net (defined as the Company’s consolidated shareholders’ equity plus the Net Financial Debt) was 37.5%, and (iii) the ratio of the Company’s Net Financial Debt to the Company’s Adjusted EBITDA[7], was 3.

The following is a reconciliation between the Company’s loss and the Adjusted EBITDA (as defined in the Series C Deed of Trust) for the four-quarter period ended

December 31, 2021

:



For the four-quarter period

ended December 31, 2021



Unaudited






in thousands


Loss for the period



(20,264)


Financing expenses, net



26,884


Tax benefit



(2,489)


Depreciation



15,076


Adjustment to revenues of the Talmei Yosef PV Plant due to calculation based on the fixed asset model



3,239


Share-based payments



49


Adjusted EBITDA as defined the Series C Deed of Trust



22,495




Information for the Company’s Series D Debenture Holders

The Deed of Trust governing the Company’s Series D Debentures includes an undertaking by the Company to maintain certain financial covenants, whereby a breach of such financial covenants for the periods set forth in the Series D Deed of Trust is a cause for immediate repayment. As of

December 31, 2021

, the Company was in compliance with the financial covenants set forth in the Series D Deed of Trust as follows: (i) the Company’s Adjusted Shareholders’ Equity (as defined in the Series D Deed of Trust) was approximately €129.2 million, (ii) the ratio of the Company’s Net Financial Debt (as set forth above) to the Company’s CAP, Net (defined as the Company’s consolidated shareholders’ equity plus the Net Financial Debt) was 34.5%, and (iii) the ratio of the Company’s Net Financial Debt to the Company’s Adjusted EBITDA[8] was 2.8.

The following is a reconciliation between the Company’s loss and the Adjusted EBITDA (as defined in the Series D Deed of Trust) for the four-quarter period ended

December 31

, 2021:



For the four quarter period

ended December 31, 2021



Unaudited






in thousands


Loss for the period



(20,264)


Financing expenses, net



26,884


Tax benefit



(2,489)


Depreciation



15,076


Adjustment to revenues of the Talmei Yosef PV Plant due to calculation based on the fixed asset model



3,239


Share-based payments



49


Talasol revenues derived during the period before the achievement of PAC



1,962


Adjusted EBITDA as defined the Series D Deed of Trust



24,457

[1]  Ellomay Solar S.L, the developer of a 28 MW solar project near the Talasol PV Plant.

[2]


The Talmei Yosef PV Plant located in

Israel

is presented under the fixed asset model and not under the financial asset model as per IFRIC 12.

[3]


Not including an amount of approximately €1 million of proceeds from the sale of electricity prior to

January 27, 2021

(the date in which the Talasol PV Plant achieved PAC).

[4]


Short-term and long-term debt from banks and other interest bearing financial obligations amount provided above, includes an amount of approximately €0.4 million costs associated with such debt, which was capitalized and therefore offset from the debt amount that is recorded in the Company’s balance sheet.

[5]


Debentures amount provided above includes an amount of approximately €2.4 million associated costs, which was capitalized and therefore offset from the debentures amount that is recorded in the Company’s balance sheet.

[6]


The project finance amount deducted from the calculation of Net Financial Debt includes project finance obtained from various sources, including financing entities and the minority shareholders in project companies held by the Company (provided in the form of shareholders’ loans to the project companies).

[7]


The term “Adjusted EBITDA” is defined in the Series C Deed of Trust as earnings before financial expenses, net, taxes, depreciation and amortization, where the revenues from the Company’s operations, such as the Talmei Yosef PV Plant, are calculated based on the fixed asset model and not based on the financial asset model (IFRIC 12), and before share-based payments. The Series C Deed of Trust provides that for purposes of the financial covenant, the Adjusted EBITDA will be calculated based on the four preceding quarters, in the aggregate. The Adjusted EBITDA is presented in this press release as part of the Company’s undertakings towards the holders of its Series C Debentures. For a general discussion of the use of non-IFRS measures, such as EBITDA and Adjusted EBITDA see above under “Use of NON-IFRS Financial Measures.”

[8]


The term “Adjusted EBITDA” is defined in the Series D Deed of Trust as earnings before financial expenses, net, taxes, depreciation and amortization, where the revenues from the Company’s operations, such as the Talmei Yosef PV Plant, are calculated based on the fixed asset model and not based on the financial asset model (IFRIC 12), and before share-based payments, when the data of assets or projects whose Commercial Operation Date (as such term is defined in the Series D Deed of Trust) occurred in the four quarters that preceded the relevant date will be calculated based on Annual Gross Up (as such term is defined in the Series D Deed of Trust). The Series D Deed of Trust provides that for purposes of the financial covenant, the Adjusted EBITDA will be calculated based on the four preceding quarters, in the aggregate. The Adjusted EBITDA is presented in this press release as part of the Company’s undertakings towards the holders of its Series D Debentures. For a general discussion of the use of non-IFRS measures, such as EBITDA and Adjusted EBITDA see above under “Use of NON-IFRS Financial Measures.”

Cision
View original content:

https://www.prnewswire.com/news-releases/ellomay-capital-reports-results-for-the-fourth-quarter-and-full-year-of-2021-301515210.html

SOURCE Ellomay Capital Ltd.